Maternal and infant RSV immunization options are considered acceptable and feasible in low- and middle-income countries if integrated into existing public health programs.
Are maternal and infant RSV immunization options feasible and acceptable in low- and middle-income countries?
Maternal and infant RSV immunization options are considered acceptable and feasible in LMICs if integrated into existing public health programs.
Absolute Event Rate: 0% vs 0%
Both maternal and infant RSV immunization options were viewed as acceptable and feasible if integrated into existing public health programs. Introduction decisions will require additional country-specific considerations, including community acceptability of option(s), health system/workforce capacity, availability of relevant epidemiology data, and product affordability. These findings can guide policymakers as they prepare for potential RSV prevention product introduction and scale-up.
Quintanar-Solares et al. (Wed,) reported a other. Maternal and infant RSV immunization options are considered acceptable and feasible in low- and middle-income countries if integrated into existing public health programs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: